Document Type : Original Article
Authors
1
professor of internal medicine, Geriatric unite, Internal Medicine department, faculty of medicine , Alexandria university
2
Geriatric unit, Internal Medicine Department, Faculty of Medicine, Alexandria university,
3
Internal medicine department, General Navy Hospital
4
clinical and chemical pathology, Faculty of medicine, Alexandria university
5
Lecturer of Nutrition, High Institute of Public Health, Faculty of Medicine, Alexandria university
Abstract
Sarcopenia is a progressive loss of skeletal muscle mass and strength. Myostatin is a myokine, and a potent negative regulator of muscle growth. This study aimed to assess the accuracy of serum myostatin in prediction of Sarcopenia in elderly patients and correlate it with QoL. The study involved 64 elderly patients aged 65 years and older; Group (I):32 sarcopenic patients, and Group (II):32 healthy age and sex-matched control participants. Participants with chronic renal, hepatic, or cardiac compensation, DM, women on hormonal replacement therapy were excluded. All participants were subjected to history taking, clinical examination, anthropocentric measurements, routine laboratory investigations, serum myostatin using ELISA, and SF-36 to assess QoL. Sarcopenia was diagnosed using EWGSOP-2 criteria. Sarcopenic patients had significantly lower ASMI, hand grip strength, and physical performance values (p<0.001). Serum Myostatin level in sarcopenic patients was significantly higher compared to controls (32.73 ± 5.0 vs. 26.49 ± 6.44 IU/dl) (p<0.001). Sarcopenic patients had significantly lower scores of SF-36 score compared to the controls (74.19 ± 5.04 vs 84.84 ± 3.33) (p<0.001).A significant negative correlation was found between serum myostatin and SF-36 scores in the sarcopenic group compared to the control group (r= -0.345; p<0.001).Serum myostatin level more than 29 (IU/dl) has sensitivity of (87.5%) and specificity of (75%) in discriminating sarcopenic patients from healthy elders. In conclusion; serum myostatin is a possible blood-based biomarker for Sarcopenia prediction as well as quality of life assessment in such population. Further researches with more sample sizes are required to confirm our outcomes.
Keywords
)
View on SCiNiTO